Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy of vortioxetine (10 to 20 mg/day) as adjunctive treatment to stable
selective serotonin reuptake inhibitor (SSRI) dose versus stable SSRI monotherapy on
cognitive performance (focusing on the aspect concerning speed of processing, executive
functioning and attention) in patients who are in partial or full remission from their Major
Depressive Episode (MDE).